Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03001323 · ClinicalTrials.gov registry record · NA
Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis
A NA study, sponsored by Hennepin Healthcare Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT03001323: Clinical Trial NA study, sponsored by Hennepin Healthcare Research Institute.
NCT03001323 is a NA study that was terminated before completion, run by Hennepin Healthcare Research Institute. The registered enrollment target is 27 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03001323, a NA study, was terminated before completion, sponsored by Hennepin Healthcare Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
Given the longer half life of insulin degludec compared to glargine /levemir ,investigators believe that insulin degludec will reduce the rate of recurrent DKA. The investigator will randomize participants to control and intervention group. Control group will receive Lantus/Levemir and intervention group will receive degludec. The investigators will call participants monthly and see them in the clinic every three months.The investigators will follow them for 1 year and evaluate if there will be a difference in rate of DKA in between these two groups.
Interventions
- DRUG Degludec
- DRUG Standard long-acting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-01 |
| Est. Completion | 2020-09-25 |
| Phase | NA |
Why NCT03001323 stopped before completion
NCT03001323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Degludec is the first listed.
NCT03001323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03001323 about?
NCT03001323 is a clinical study titled "Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis". Given the longer half life of insulin degludec compared to glargine /levemir ,investigators believe that insulin degludec will reduce the rate of recurrent DKA. The investigator will randomize participants to control and intervention group. Control group will receive Lantus/Levemir and intervention ...
What is the current status of trial NCT03001323?
This trial is currently terminated. It is a NA study. The enrollment target is 27 participants. The study started on 2017-01. Estimated completion is 2020-09-25.
What interventions are being tested in trial NCT03001323?
The interventions under investigation include: Degludec (DRUG), Standard long-acting (DRUG).
Who is sponsoring clinical trial NCT03001323?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03001323's enrollment target sits among peer trials
27 1708th of 2000 higher than 291 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia